Cassava Sciences, Inc.

The writing has been on the wall for some time, but Cassava Sciences has now officially given up on its Alzheimer’s disease candidate, simufilam, after it failed in a second Phase III trial, REFOCUS-A

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. CytomX, Amgen Decision Follows January

Public biopharma companies usually spend the week before the J.P. Morgan Healthcare Conference announcing new financings, partnerships and sometimes data so that they have compelling milestones to dis

The long and arduous development path for Cassava Sciences’ simufilam in mild-to-moderate Alzheimer’s disease appears to have come to its end now that the drug failed to deliver statistically signific